Pancreatic Cancer Research Pancreatic Cancer Research

With only an 8% five-year survival rate1, pancreatic cancer is the 3rd leading cause of cancer-related death1 and Boston Scientific is committed to changing this alarming statistic by supporting organizations such as The Lustgarten Foundation, the Pancreatic Cancer Action Network and National Pancreas Foundation.

In support of Pancreatic Cancer Awareness Month, Boston Scientific donated $75,000 of global WallFlex™ Biliary RX Stent, Acquire™ Endoscopic Ultrasound Fine Needle Biopsy Device, and SpyScope™ DS sales made in November to these three organizations to help fund pancreatic cancer research, education and awareness.

Program Details:
Boston Scientific donated 1% of sales for products used to diagnose and treat conditions caused by pancreatic cancer during the month of November to three non-profit organizations, with a maximum donation amount of $75,000. This program applies to fully covered, partially covered and uncovered WallFlex RX Biliary Stents, Acquire 22ga and 25ga Endoscopic Ultrasound Fine Needle Biopsy Devices, and SpyScope DS devices sold from November 1-30, 2016.